Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Virbac's share price for the quarter that ended in Dec. 2025 was €342.75. Virbac's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 8 Mil. Therefore, Virbac's market cap for the quarter that ended in Dec. 2025 was €2,872 Mil.
Virbac's quarterly market cap
declined
from Dec. 2024 (€2,743 Mil) to Jun. 2025 (€2,662 Mil) but then
increased
from Jun. 2025 (€2,662 Mil) to Dec. 2025 (€2,872 Mil).
Virbac's annual market cap
increased
from Dec. 2023 (€2,381 Mil) to Dec. 2024 (€2,743 Mil) and
increased
from Dec. 2024 (€2,743 Mil) to Dec. 2025 (€2,872 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Virbac's Enterprise Value for Today is €2,953 Mil.
Virbac (CHIX:VIRPp) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Virbac Market Cap Related Terms
Virbac Market Cap Historical Data
* Premium members only.
The historical data trend for Virbac's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VIRPP vs LLY, JNJ, ABBV: Market Cap Comparison
For the Drug Manufacturers - General subindustry, Virbac's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virbac Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Virbac's Market Cap distribution charts can be found below:
* The bar in red indicates where Virbac's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Virbac's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virbac (CHIX:VIRPP) has a Market Cap of €2,787 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Virbac and its competitors. According to the industry distribution chart, Virbac ranks #104 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 10.2%.
Is Virbac's Market Cap too high?
Virbac's current Market Cap is €2,787 Mil. Based on the distribution chart, Virbac ranks #104 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Virbac has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #104 out of 1020 companies for Market Cap. This places Virbac in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 213.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.67, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Virbac and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current Market Cap is €2,787 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current Market Cap of €2,787 Mil. The stock's GF Value™ is €377.67, compared to a current price of €354.25 — trading 6.2% below its estimated fair value. The current Market Cap is €2,787 Mil. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Market Cap is €2,787 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virbac (CHIX:VIRPP) Overvalued in 2026?
Based on GuruFocus' analysis, Virbac stock appears to be undervalued.
The current stock price of €354.25 is trading 6.2% below its estimated GF Value™ of €377.67.
Key valuation signals for CHIX:VIRPP:
Market Cap: €2,787 Mil
GF Value™: €377.67 vs. price of €354.25 (6.2% below fair value)
No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score
Get the complete analysis for CHIX:VIRPP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VIRPP has been successfully added to your 
